Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 2 , Pages 229-241 , April 2008

Intra-prostatic androgen levels during various androgen-blockade regimens

  • Tsutomu Nishiyama, MD, PhD (Associate Professor)

      Affiliations

    • Corresponding Author InformationTel.: +81 25 227 2285; Fax: +81 25 227 0784.

References 

  1. Isaacs JT. Testosterone and the prostate. In:  Nieschlag E,  Behre HM,  Niechlag S editor. Testosterone. 3rd ed.. Cambridge University Press; 2004;p. 347–374
  2. Huggins C, Hodges CV. Studies on prostate cancer. Effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research. 1941;1:293–297
  3. Labrie F, Dupont A, Belanger A, et al. Combination therapy with flutamide and castration (LH-RH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. Journal of Steroid Biochemistry. 1985;23:833–841
  4. Crawford ED, Allen JA. Treatment of newly diagnosed state D2 prostate cancer with leuprolide and flutamide or leuprolide alone, phase III, intergroup study 0036. The Journal of Steroid Biochemistry and Molecular Biology. 1990;37:961–963
  5. Prostate Cancer Trialists' Collaborative Group . Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet. 2000;355:1491–1498
  6. Klotz L. Combined androgen blockade in prostate cancer: meta-analyses and associated issues. BJU International. 2001;87:806–813
  7. Labrie F, Belanger A, Luu-The V, et al. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocrine Reviews. 2005;26:361–379
  8. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. The New England Journal of Medicine. 1998;339:1036–1042
  9. Labrie F, Candas B, Gomez JL, et al. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?. Urology. 2002;60:115–119
  10. McConnell JD, Wilson JD, George FW, et al. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. The Journal of Clinical Endocrinology and Metabolism. 1992;74:505–508
  11. Labrie F, Belanger A, Dupont A, et al. Science behind total androgen blockade: from gene to combination therapy. Clinical and Investigative Medicine. 1993;16:475–492
  12. Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen eprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clinical Cancer Research. 2004;10:7121–7126
  13. Eaton NE, Reeves GK, Appleby PN, et al. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. British Journal of Cancer. 1999;80:930–934
  14. Shaneyfelt T, Husein R, Bubley G, et al. Hormonal predictors of prostate cancer: a meta-analysis. Journal of Clinical Oncology. 2000;18:847–853
  15. Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer?. The Journal of Urology. 2000;163:824–827
  16. Schatzl G, Madersbacher S, Thurridl T, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate. 2001;47:52–58
  17. Massengill JC, Sun L, Moul JW, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. The Journal of Urology. 2003;169:1670–1675
  18. Isom-Batz G, Bianco FJ, Kattan MW, et al. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. The Journal of Urology. 2005;173:1935–1937
  19. Teloken C, Da Ros CT, Caraver F, et al. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. The Journal of Urology. 2005;174:2178–2180
  20. Prehn RT. On the prevention and therapy of prostate cancer by androgen administration. Cancer Research. 1999;59:4161–4164
  21. Rommerts FFG. Testosterone: an overview of biosynthesis, transport, metabolism and non-genomic actions. In:  Nieschlag E,  Behre HM,  Niechlag S editor. Testosterone. 3rd ed.. Cambridge University Press; 2004;p. 1–37
  22. Nishiyama T, Ikarashi T, Hashimoto Y, et al. Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score. The Journal of Urology. 2006;176:1387–1391
  23. Freedland SJ, Isaacs WB, Platz EA, et al. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. Journal of Clinical Oncology. 2005;23:7546–7554
  24. Cunningham JM, Hebbring SJ, McDonnell SK, et al. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiology, Biomarkers and Prevention. 2007;16:969–978
  25. Cussenot O, Azzouzi AR, Nicolaiew N, et al. Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5 alpha-reductase inhibitors. European Urology. 2007 Oct;52(4):1082–1087
  26. D'Amico F, Biancolella M, Margiotti K, et al. Genomic biomarkers, androgen pathway and prostate cancer. Pharmacogenomics. 2007;8:645–661
  27. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. The New England Journal of Medicine. 2003;349:215–224
  28. Rubin MA, Allory Y, Molinie V, et al. Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome. Urology. 2005;66:930–934
  29. Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute. 2007;99:1375–1383
  30. Hammond GL. Endogenous steroid levels in the human prostate from birth to old age: a comparison of normal and diseased tissues. The Journal of Endocrinology. 1978;78:7–19
  31. Belanger B, Belanger A, Labrie F, et al. Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. Journal of Steroid Biochemistry. 1989;32:695–698
  32. Geller J, Albert JD. Effects of castration compared with total androgen blockade on tissue dihydrotestosterone (DHT) concentration in benign prostatic hyperplasia (BPH). Urological Research. 1987;15:151–153
  33. Nishiyama T, Ikarashi T, Hashimoto Y, et al. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score. The Journal of Urology. 2007;178:1282–1289
  34. Nakamura Y, Suzuki T, Nakabayashi M, et al. In situ androgen producing enzymes in human prostate cancer. Endocrine-Relatated Cancer. 2005;12:101–107
  35. Fung KM, Samara EN, Wong C, et al. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocrine-Relatated Cancer. 2006;13:169–180
  36. Wako K, Kawasaki T, Yamana K, et al. Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer. Journal of Clinical Pathology. 2007;(Epub ahead of print)
  37. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Research. 2006;66:2815–2825
  38. Li R, Wheeler T, Dai H, et al. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. American Journal of Surgical Pathology. 2004;28:928–934
  39. Morote J, Orsola A, Planas J, et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. The Journal of Urology. 2007;178:1290–1295
  40. Ellem SJ, Risbridger GP. Treating prostate cancer: a rationale for targeting local oestrogens. Nature Reviews: Cancer. 2007;7:621–627
  41. Balzano S, Cappa M, Migliari R, et al. The effect of flutamide on basal and ACTH-stimulated plasma levels of adrenal androgens in patients with advanced prostate cancer. Journal of Endocrinological Investigation. 1988;11:693–696
  42. Ayub M, Levell MJ. Suppression of plasma androgens by the antiandrogen flutamide in prostatic cancer patients treated with Zoladex, a GnRH analogue. Clinical Endocrinology. 1990;32:329–339
  43. Carlstrom K, Pousette A, Stege R. Flutamide has no effect on adrenal androgen response to acute ACTH stimulation in patients with prostatic cancer. Prostate. 1990;17:219–225
  44. Xu Y, Dalrymple SL, Becker RE, et al. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clinical Cancer Research. 2006;12:4072–4079
  45. Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/ two enzymes. Annual Review of Biochemistry. 1994;63:25–61
  46. Thomas LN, Lazier CB, Gupta R, et al. Differential alterations in 5 alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate. 2005;63:231–239
  47. Titus MA, Gregory CW, Ford OH, et al. Steroid 5 alpha-reductase isozymes I and II in recurrent prostate cancer. Clinical Cancer Research. 2005;11:4365–4371
  48. Gleave M, Qian J, Andreou C, et al. The effects of the dual 5 alpha-reductase inhibitor dutasteride on localized prostate cancer–results from a 4-month pre-radical prostatectomy study. Prostate. 2006;66:1674–1685
  49. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA: The Journal of the American Medical Association. 2005;294:238–244
  50. Mohler JL, Gregory CW, Ford OH, et al. The androgen axis in recurrent prostate cancer. Clinical Cancer Research. 2004;10:440–448
  51. Titus MA, Schell MJ, Lih FB, et al. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clinical Cancer Research. 2005;11:4653–4657
  52. Suzuki K, Nishiyama T, Hara N, et al. Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. Prostate Cancer Prostatic Diseases. 2007;10:301–306
  53. Lam JS, Leppert JT, Vemulapalli SN, et al. Secondary hormonal therapy for advanced prostate cancer. The Journal of Urology. 2006;175:27–34
  54. Ryan CJ, Halabi S, Ou SS, et al. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. Clinical Cancer Research. 2007;13:2030–2037
  55. Mostaghel EA, Page ST, Lin DW, et al. Intra-prostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Research. 2007;67:5033–5041

PII: S1521-690X(08)00003-1

doi: 10.1016/j.beem.2008.01.002

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 2 , Pages 229-241 , April 2008

Article Tools

* Image Usage & Resolution